Evidence map›Paper›PMID 25210405›Full record

ArticleJournal of pharmacology & pharmacotherapeutics2014

Angioedema due to fixed dose combination of telmisartan plus ramipril.

Vishal R Tandon, Annil Mahajan, Vijay Khajuria, Zahid H Gillani

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacology & pharmacotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Telmisartan-induced angioedema: A rare clinical finding.Journal of family medicine and primary care · 2022
    Article
  2. Hyperpigmentation Induced by Combination Therapy With Telmisartan-Hydrochlorothiazide.Journal of clinical hypertension (Greenwich, Conn.) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vishal R TandonDepartment of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India.
Annil MahajanDepartment of General Medicine, Government Medical College, Jammu, Jammu and Kashmir, India.
Vijay KhajuriaDepartment of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India.
Zahid H GillaniDepartment of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India.
Government Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk for angioedema has been suggested lower with angiotensin receptor blockers (ARBs) than with angiotensin-converting enzyme inhibitors (ACEIs) or aliskiren. Many isolated reports do exist, reporting angioedema with ARBs such as olmesartan, valsartan, losartan and telmisartan. To the best of our knowledge this is the first case report of telmisartan plus ramipril fixed dose combination leading to angioedema from India questioning the rationality of ARBs plus ACEIs combination in the treatment of hypertension.

Indexed as

Angiotensin-converting enzyme inhibitorsangiotensin receptor blockersfixed dose combinationRamiprilTelmisartan

Identifiers

PMID25210405
PMCPMC4156836
OpenAlexW1977744236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.